Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $3.98 per share, missing the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $4.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -0.25%. A quarter ago, it was expected that this drugmaker would post earnings of $4.13 per share when it actually produced earnings of $4.38, delivering a surprise of 6.05%.Over the last four quarters, the ...

Revenue Performance - Full year product revenue reached $11.02 billion, a 12% increase compared to 2023[1] - Fourth quarter product revenue increased 16% to $2.91 billion compared to Q4 2023, driven by strong performance of TRIKAFTA/KAFTRIO[4] - Net product revenue in the U.S. for the full year increased 11% to $6.68 billion, while outside the U.S. it increased 13% to $4.34 billion[9] - Vertex reported product revenues of $2,912.0 million for Q4 2024, a 15.7% increase from $2,517.7 million in Q4 2023[39] - For the full year 2024, product revenues reached $11,020.1 million, up 11.6% from $9,869.2 million in 2023[39] Financial Guidance and Projections - The company provided full year 2025 total revenue guidance of $11.75 to $12.0 billion, anticipating continued growth from new product launches[15] - Vertex expects to launch ALYFTREK for cystic fibrosis and JOURNAVX for acute pain in 2025, contributing to revenue growth[2] - Vertex anticipates the number of cystic fibrosis patients using its medicines to grow, supported by recent approvals and reimbursement agreements[19] Expenses and Losses - Combined GAAP and Non-GAAP R&D and SG&A expenses for the full year 2024 were $5.1 billion and $4.2 billion, respectively, reflecting increased investment in R&D and commercial activities[10] - GAAP net loss for 2024 was $(536) million, compared to net income of $3.6 billion in 2023, primarily due to higher AIPR&D expenses related to the acquisition of Alpine Immune Sciences[13] - Vertex's total costs and expenses for Q4 2024 were $1,886.0 million, an increase from $1,529.2 million in Q4 2023[39] Research and Development - Research and development expenses for Q4 2024 were $998.7 million, compared to $824.6 million in Q4 2023, reflecting a 21.1% increase[39] - Vertex expects to complete enrollment in the interim analysis cohort for the AMPLITUDE trial in 2025, with potential accelerated approval for inaxaplin in the U.S. thereafter[29] - The company is also enrolling patients in the global Phase 3 RAINIER study for povetacicept, with expected completion of enrollment in 2025[30] - Vertex's lead approach for Myotonic Dystrophy Type 1, VX-670, is currently in the multiple ascending dose portion of a global Phase 1/2 clinical trial[32] - The company anticipates advancing VX-407 into a Phase 2 proof-of-concept study for Autosomal Dominant Polycystic Kidney Disease in 2025[33] - Plans to advance VX-522, a nebulized mRNA therapy, with data expected in the first half of 2025[52] - The company aims to complete dosing in studies evaluating CASGEVY in children aged 5 to 11 years in 2025[52] - Vertex is focused on developing new oral small molecule combination therapies for CF and advancing its pipeline across various serious diseases[50] Cash and Equity - Vertex's cash, cash equivalents, and total marketable securities decreased to $11.2 billion as of December 31, 2024, from $13.7 billion in 2023, due to acquisition costs and stock repurchases[14] - Total current assets decreased to $9,596.4 million in December 2024 from $14,144.2 million in December 2023, a decline of 32.2%[49] - Cash, cash equivalents, and marketable securities decreased to $6,115.9 million in December 2024 from $11,218.3 million in December 2023, a drop of 45.5%[49] - Shareholders' equity decreased to $16,409.6 million in December 2024 from $17,580.4 million in December 2023, a decrease of 6.7%[49] Tax Rates - Vertex's effective tax rates for 2024 were significantly higher at 315.5% GAAP and 91.0% Non-GAAP, primarily due to non-deductible AIPR&D expenses[12] Collaborations and Market Expansion - The company has entered into a collaboration with Zai Lab for the development of povetacicept in several Asian markets, signed in January 2025[34] - The company anticipates continued growth in cystic fibrosis (CF) treatments, including the launch of ALYFTREK and expansion into additional geographies[52] - Expectations for the commercial launch of JOURNAVX for acute pain treatment, with retail availability beginning shortly after the end of the month[52]

Vertex Pharmaceuticals Incorporated (VRTX) will report fourth-quarter and full-year 2024 earnings result on Feb. 10, after market close. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $2.77 billion and $3.99 per share, respectively. Earnings estimates for Vertex for 2025 have declined from $18.25 to $18.19 per share over the past 30 days.See the Zacks Earnings Calendar to stay ahead of market-making news.Image Source: Zacks Investment ResearchVRTX's Earnings Surprise ...

The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast revenues of $2.77 billion, representing an increase of 10% year over year.Over the last 30 days, there has been a downward revision of 2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the co ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8% gain over the past four weeks.Last week, the company announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate-to-severe acute pain. The drug will be marketed by the name of Journavx ...

Vertex Pharmaceuticals Incorporated (VRTX) announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate-to-severe acute pain. The pain drug will be marketed by the name of Journavx.Following the nod, Journavx has become the first and only non-opioid oral pain signal inhibitor and the first new class of pain medicine to be approved by the FDA in more than 20 years.Per the company, Journavx has the potential to ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug Administration (FDA) approved the biotech's new non-opioid painkiller, Journavx. In a statement to the press, the company said it was the "first new class of pain treatment approved in more than 20 years." In response, Scotiabank raised its price target on VRTX by $3 to $433. Now recovered from its mid-December bear gap, VRTX is already up 15.7% since the start of 2025. Today's pop has the stock b ...

POLAND - 2024/11/21: In this photo illustration, the Vertex Pharmaceuticals company logo is seen ... [+] displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesVertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can potentially garner $4 billion in annual peak sales. For perspectiv ...

Stock Performance - Vertex Pharmaceuticals closed at $440 68, down 0 72% from the previous session, underperforming the S&P 500's gain of 0 92%, the Dow's gain of 0 31%, and the Nasdaq's gain of 2 03% [1] - Over the past month, the company's shares gained 11 15%, outperforming the Medical sector's gain of 3 83% and the S&P 500's gain of 0 81% [1] Earnings and Revenue - The company's upcoming earnings report is expected on February 10, 2025, with projected EPS of $4, reflecting a 4 76% decrease from the same quarter last year [2] - Revenue is expected to be $2 78 billion, up 10 29% from the prior-year quarter [2] Analyst Forecasts and Revisions - Recent revisions to analyst forecasts for Vertex Pharmaceuticals are important as they reflect changing near-term business trends [3] - Positive estimate revisions are generally a good sign for the company's business outlook [3] - The Zacks Consensus EPS estimate has shifted 0 34% downward over the past month [5] Valuation Metrics - Vertex Pharmaceuticals is trading at a Forward P/E ratio of 24 39, which is a premium compared to the industry average of 22 85 [6] - The company has a PEG ratio of 2, higher than the industry average of 1 39 for Medical - Biomedical and Genetics stocks [6] Industry Ranking - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 72, placing it in the top 29% of over 250 industries [7] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks within the groups [7] - Top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, t ...